The FDA has accepted Santarus and Pharming Group's regulatory application for Ruconest as a treatment for acute hereditary angioedema attacks. The firms expect the FDA to release its decision by April 16.
Published in Brief:
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||